Last reviewed · How we verify
Pangramin SLIT HDM mix.
Pangramin SLIT HDM mix is a sublingual immunotherapy that desensitizes the immune system to house dust mite allergens through repeated exposure to gradually increasing doses.
Pangramin SLIT HDM mix is a sublingual immunotherapy that desensitizes the immune system to house dust mite allergens through repeated exposure to gradually increasing doses. Used for Allergic rhinitis and/or asthma induced by house dust mite allergens.
At a glance
| Generic name | Pangramin SLIT HDM mix. |
|---|---|
| Sponsor | ALK-Abelló A/S |
| Drug class | Sublingual immunotherapy (SLIT) |
| Modality | Biologic |
| Therapeutic area | Immunology / Allergy |
| Phase | Phase 3 |
Mechanism of action
This sublingual immunotherapy (SLIT) product contains a standardized mixture of house dust mite (HDM) allergen extracts designed to induce immune tolerance. By administering small amounts of allergen under the tongue, the treatment promotes a shift from Th2-mediated allergic responses toward Th1/Treg-mediated tolerance, reducing allergic symptoms and airway hyperresponsiveness over time.
Approved indications
- Allergic rhinitis and/or asthma induced by house dust mite allergens
Common side effects
- Oral pruritus
- Throat irritation
- Local mouth edema
- Gastrointestinal symptoms
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pangramin SLIT HDM mix. CI brief — competitive landscape report
- Pangramin SLIT HDM mix. updates RSS · CI watch RSS
- ALK-Abelló A/S portfolio CI